P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

ClinicalTrials.gov ID: NCT06014762

Public ClinicalTrials.gov record NCT06014762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Study identification

NCT ID: NCT06014762
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

P-CD19CD20-ALLO1 Biological
Rimiducid Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 16, 2024 (Actual)
Primary completion: Mar 2029 (Estimated)
Completion: Mar 2041 (Estimated)
Last update posted: May 7, 2026

2024 – 2041

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Loma Linda University Cancer Center	Loma Linda	California	92354	—
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
Advent Health Orlando	Orlando	Florida	32803	—
Indiana University	Indianapolis	Indiana	46202	—
Our Lady of the Lake Hospital	Baton Rouge	Louisiana	70808	—
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	—
Wayne State - Karmanos Cancer Institute	Detroit	Michigan	48201	—
NYU Grossman School of Medicine	New York	New York	10016	—
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	27599	—
University of Cincinnati	Cincinnati	Ohio	45206	—
University of Oklahoma, Health Sciences Center	Oklahoma City	Oklahoma	73104	—
Oregon Health & Science University	Portland	Oregon	97239	—
Pennsylvania State University	Hershey	Pennsylvania	17033	—
Prisma Health - Upstate Cancer Institute	Greenville	South Carolina	29605	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
Baylor Scott & White Research Institute	Dallas	Texas	75204	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06014762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2026 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06014762 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →